C
Carlo M. Croce
Researcher at Ohio State University
Publications - 1156
Citations - 199822
Carlo M. Croce is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 198, co-authored 1135 publications receiving 189007 citations. Previous affiliations of Carlo M. Croce include University of Nebraska Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
Xi Rao,G Di Leva,Meng Li,Fang Fang,C. Devlin,Corinna Hartman-Frey,Matthew E. Burow,Mircea Ivan,Carlo M. Croce,Kenneth P. Nephew +9 more
TL;DR: This first in-depth investigation into the role of miR-221/222 in acquired fulvestrant resistance demonstrates that these two ‘oncomirs’ may represent promising therapeutic targets for treating hormone-independent, SERD-resistant breast cancer.
Journal ArticleDOI
MicroRNA Cluster 221-222 and Estrogen Receptor α Interactions in Breast Cancer
Gianpiero Di Leva,Pierluigi Gasparini,Claudia Piovan,Apollinaire Ngankeu,Michela Garofalo,Cristian Taccioli,Marilena V. Iorio,Meng Li,Stefano Volinia,Hansjuerg Alder,Tatsuya Nakamura,Gerard J. Nuovo,Yunlong Liu,Kenneth P. Nephew,Carlo M. Croce +14 more
TL;DR: The findings suggest that the negative regulatory loop involving miR-221-222 and ERalpha may confer proliferative advantage and migratory activity to breast cancer cells and promote the transition from ER-positive to ER-negative tumors.
Journal ArticleDOI
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.
Michela Garofalo,Cristina Quintavalle,G Di Leva,Ciro Zanca,Giulia Romano,Cristian Taccioli,Chang Gong Liu,Carlo M. Croce,Gerolama Condorelli +8 more
TL;DR: It is shown that high expression levels of miR-221 and -222 are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.
Journal ArticleDOI
Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression
Fengmei Pi,Daniel W. Binzel,Tae Jin Lee,Tae Jin Lee,Zhefeng Li,Meiyan Sun,Piotr G. Rychahou,Hui Li,Farzin Haque,Shaoying Wang,Carlo M. Croce,Bin Guo,B. Mark Evers,Peixuan Guo +13 more
TL;DR: The orientation of arrow-shaped RNA was altered to control ligand display on extracellular vesicle membranes for specific cell targeting, or to regulate intracellular trafficking of small interfering RNA (siRNA) or microRNA (miRNA) in cancer treatment.
Journal ArticleDOI
Chronic lymphocytic leukaemia.
Thomas J. Kipps,Freda K. Stevenson,Catherine J. Wu,Carlo M. Croce,Graham Packham,William G. Wierda,Susan O'Brien,John G. Gribben,Kanti R. Rai +8 more
TL;DR: Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and lymphoid tissues as mentioned in this paper.